CoChat
Sign Up
Cited by 978Liver Disease and TransplantationAbdominal vascular conditions and treatmentsLiver Diseases and Immunity

Vascular disorders of the liver # †

Open access
DeLeve, Laurie D., Valla, Dominique-Charles, Garcia-Tsao, Guadalupe·2009·Hepatology
DOI 10.1002/hep.22772PMC PMC6697263
Open this paper in CoChat — free accountOpen PDF

Abstract

This guideline has been approved by the American Association for the Study of Liver Diseases (AASLD) and represents the position of the association. PreambleThese recommendations provide a data-supported approach.They are based on the following: (1) formal review and analysis of the recently published world literature on the topic (Medline search); (2) American College of Physicians Manual for Assessing Health Practices and Designing Practice Guidelines 1 ; (3) guideline policies, including the AASLD Policy on the Development and Use of Practice Guidelines and the American Gastroenterological Association Policy Statement on Guidelines 2 ; and (4) the experience of the authors in the specified topic.Intended for use by physicians, these recommendations suggest preferred approaches to the diagnostic, therapeutic, and preventive aspects of care.They are intended to be flexible, in contrast to standards of care, which are inflexible policies to be followed in every case.Specific recommendations are based on relevant published information.To more fully characterize the quality of evidence supporting recommendations, the Practice Guidelines Committee of the AASLD requires a Class (reflecting benefit versus risk) and Level (assessing strength or certainty) of Evidence to be assigned and reported with each recommendation (Table 1, adapted from the American College of Cardiology and the American Heart Association Practice Guidelines.3,4 )

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/hep.22772

Cites

1 of 1 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • A thorough investigation can identify further local triggering factors in as many as 30-40% of cases of acute mesenteric venous thrombosis.

    “A thorough investigation can identify one or more systemic prothrombotic factors in approximately 60 e 70% of patients with AMVT, and further local triggering factors in as many as 30 e 40% of cases. 202,204,210”

    From Editor's Choice - European Society for Vascular Surgery (ESVS) 2025 Clinical Practice Guidelines on the Management of Diseases of the Mesenteric and Renal Arteries and Veins. (2025) · cites this paper as [202]

    The Causes of Portal Vein Thrombosis section says a local risk factor can be identified in about 30% of patients, and the Local Factors subsection says such factors are more often recognized in acute than chronic PVT. It does not give a 30–40% figure for acute mesenteric venous thrombosis specifically, so the claim extends the finding to a different condition. (LLM, conf=0.85)

    Experimental — accuracy not yet measured

  • A thorough investigation can identify one or more systemic prothrombotic factors in approximately 60-70% of patients with acute mesenteric venous thrombosis.

    “A thorough investigation can identify one or more systemic prothrombotic factors in approximately 60 e 70% of patients with AMVT, and further local triggering factors in as many as 30 e 40% of cases. 202,204,210”

    From Editor's Choice - European Society for Vascular Surgery (ESVS) 2025 Clinical Practice Guidelines on the Management of Diseases of the Mesenteric and Renal Arteries and Veins. (2025) · cites this paper as [202]

    The ‘Causes of Portal Vein Thrombosis’ section says a general risk factor is identified in 70% of patients with portal vein thrombosis. It does not establish that approximately 60–70% of patients specifically with acute mesenteric venous thrombosis have systemic prothrombotic factors. (LLM, conf=0.88)

    Experimental — accuracy not yet measured

  • In approximately 20-30% of patients with acute mesenteric venous thrombosis, no underlying aetiology or causal factor can be identified.

    “In the 20 e 30% of patients in whom the underlying aetiology cannot be identified, AMVT is considered unprovoked or idiopathic.”

    From Editor's Choice - European Society for Vascular Surgery (ESVS) 2025 Clinical Practice Guidelines on the Management of Diseases of the Mesenteric and Renal Arteries and Veins. (2025) · cites this paper as [202]

    The Causes of Portal Vein Thrombosis section reports risk-factor frequencies for portal vein thrombosis, not the proportion of acute mesenteric venous thrombosis (AMVT) cases with no identifiable cause. Searches for idiopathic or unexplained AMVT and the 20–30% figure found no passage in our copy supporting the claim; the References section merely lists studies of mesenteric venous thrombosis. (LLM, conf=0.73)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 366

  1. [1]Eddy DM. A Manual for Assessing Health Practices and Designing Practice Guidelines. Philadelphia, PA: American College of Physicians; 1996: 1– 126.
  2. [2]Position and policy statement: American Gastroenterological Association policy statement on the use of medical practice guidelines by managed care organizations and insurance carriers. Gastroenterology 1995; 108: 925– 926. 7875497
  3. [3]Shiffman RN, Shekelle P, Overhage JM, Slutsky J, Grimshaw J, Deshpande AM. Standardized reporting of clinical practice guidelines: a proposal from the conference on guideline standardization. Ann Intern Med 2003; 139: 493– 498. 13679327
  4. [5]Ogren M, Bergqvist D, Bjorck M, Acosta S, Eriksson H, Sternby NH. Portal vein thrombosis: prevalence, patient characteristics and lifetime risk: a population study based on 23,796 consecutive autopsies. World J Gastroenterol 2006; 12: 2115– 2119. 16610067 PMC4087695
  5. [6]Arora NK, Lodha R, Gulati S, Gupta AK, Mathur P, Joshi MS, Portal hypertension in north Indian children. Indian J Pediatr 1998; 65: 585– 591. 10773909
  6. [7]Condat B, Pessione F, Denninger MH, Hillaire S, Valla D. Recent portal or mesenteric venous thrombosis: increased recognition and frequent recanalization on anticoagulant therapy. Hepatology 2000; 32: 466– 470. 10960436
  7. [8]Chamouard P, Pencreach E, Maloisel F, Grunebaum L, Ardizzone JF, Meyer A, Frequent factor II G20210A mutation in idiopathic portal vein thrombosis. Gastroenterology 1999; 116: 144– 148. 9869612
  8. [9]Janssen HL, Meinardi JR, Vleggaar FP, van Uum SH, Haagsma EB, van Der Meer FJ, Factor V Leiden mutation, prothrombin gene mutation, and deficiencies in coagulation inhibitors associated with Budd-Chiari syndrome and portal vein thrombosis: results of a case-control study. Blood 2000; 96: 2364– 2368. 11001884
  9. [10]Primignani M, Martinelli I, Bucciarelli P, Battaglioli T, Reati R, Fabris F, Risk factors for thrombophilia in extrahepatic portal vein obstruction. Hepatology 2005; 41: 603– 608. 15726653
  10. [11]Denninger MH, Chait Y, Casadevall N, Hillaire S, Guillin MC, Bezeaud A, Cause of portal or hepatic venous thrombosis in adults: the role of multiple concurrent factors. Hepatology 2000; 31: 587– 591. 10706547
  11. [12]Plemmons RM, Dooley DP, Longfield RN. Septic thrombophlebitis of the portal vein (pylephlebitis): diagnosis and management in the modern era. Clin Infect Dis 1995; 21: 1114– 1120. 8589130
  12. [13]Webb LJ, Sherlock S. The aetiology, presentation and natural history of extra-hepatic portal venous obstruction. Q J Med 1979; 48: 627– 639. 538223
  13. [14]Bhattacharyya M, Makharia G, Kannan M, Ahmed RP, Gupta PK, Saxena R. Inherited prothrombotic defects in Budd-Chiari syndrome and portal vein thrombosis: a study from North India. Am J Clin Pathol 2004; 121: 844– 847. 15198356
  14. [15]Mahmoud AE, Elias E, Beauchamp N, Wilde JT. Prevalence of the factor V Leiden mutation in hepatic and portal vein thrombosis. Gut 1997; 40: 798– 800. 9245936 PMC1027208
  15. [16]Mohanty D, Shetty S, Ghosh K, Pawar A, Abraham P. Hereditary thrombophilia as a cause of Budd-Chiari syndrome: a study from Western India. Hepatology 2001; 34: 666– 670. 11584361
  16. [17]Ahuja V, Marwaha N, Chawla Y, Dilawari JB. Coagulation abnormalities in idiopathic portal venous thrombosis. J Gastroenterol Hepatol 1999; 14: 1210– 1211. 10634159
  17. [18]Amitrano L, Brancaccio V, Guardascione MA, Margaglione M, Iannaccone L, Dandrea G, High prevalence of thrombophilic genotypes in patients with acute mesenteric vein thrombosis. Am J Gastroenterol 2001; 96: 146– 149. 11197244
  18. [19]Egesel T, Buyukasik Y, Dundar SV, Gurgey A, Kirazli S, Bayraktar Y. The role of natural anticoagulant deficiencies and factor V Leiden in the development of idiopathic portal vein thrombosis. J Clin Gastroenterol 2000; 30: 66– 71. 10636214
  19. [20]Fennerty A. Venous thromboembolic disease and cancer. Postgrad MedJ 2006; 82: 642– 648. 17068274 PMC2653906
  20. [21]Aird WC. Sepsis and coagulation. Crit Care Clin 2005; 21: 417– 431. 15992665
  21. [22]Chait Y, Condat B, Cazals-Hatem D, Rufat P, Atmani S, Chaoui D, Relevance of the criteria commonly used to diagnose myeloproliferative disorder in patients with splanchnic vein thrombosis. Br J Haematol 2005; 129: 553– 560. 15877740
  22. [23]Valla D, Casadevall N, Huisse MG, Tulliez M, Grange JD, Muller O, Etiology of portal vein thrombosis in adults. A prospective evaluation of primary myeloproliferative disorders. Gastroenterology 1988; 94: 1063– 1069. 3345875
  23. [24]Colaizzo D, Amitrano L, Tiscia GL, Scenna G, Grandone E, Guardascione MA, The JAK2 V617F mutation frequently occurs in patients with portal and mesenteric venous thrombosis. J Thromb Haemost 2007; 5: 55– 61. 17059429
  24. [25]De Stefano V, Fiorini A, Rossi E, Za T, Farina G, Chiusolo P, Prevalence of the JAK2(V617F) mutation among patients with splanchnic or cerebral venous thrombosis and without overt chronic myeloproliferative disorders. J Thromb Haemost 2007; 5: 708– 714. 17263783
  25. [26]Kiladjian JJ, Cervantes F, Leebeek FW, Marzac C, Cassinat B, Chevret S, The impact of JAK2 and MPL mutations on diagnosis and prognosis of splanchnic vein thrombosis. A report on 241 cases. Blood 2008; 111: 4022– 4029. 18250227
  26. [27]Primignani M, Barosi G, Bergamaschi G, Gianelli U, Fabris F, Reati R, Role of the JAK2 mutation in the diagnosis of chronic myeloproliferative disorders in splanchnic vein thrombosis. Hepatology 2006; 44: 1528– 1534. 17133457
  27. [28]Fisher NC, Wilde JT, Roper J, Elias E. Deficiency of natural anticoagulant proteins C, S, and antithrombin in portal vein thrombosis: a secondary phenomenon? Gut 2000; 46: 534– 539. 10716684 PMC1727871
  28. [29]Amitrano L, Guardascione MA, Brancaccio V, Margaglione M, Manguso F, Iannaccone L, Risk factors and clinical presentation of portal vein thrombosis in patients with liver cirrhosis. J Hepatol 2004; 40: 736– 741. 15094219
  29. [30]Duchmann JC, Joly JP, Biny JP, Sevestre H, Capron JP. Portal thrombosis and liver cirrhosis. Value of ultrasound-guided puncture-biopsy of the thrombus. [in French] Gastroenterol Clin Biol 1995; 19: 581– 586. 7590023
  30. [31]Tarantino L, Francica G, Sordelli I, Esposito F, Giorgio A, Sorrentino P, Diagnosis of benign and malignant portal vein thrombosis in cirrhotic patients with hepatocellular carcinoma: color Doppler US, contrast-enhanced US, and fine-needle biopsy. Abdom Imaging 2006; 31: 537– 544. 16865315
  31. [32]Trum JW, Valla D, Cohen G, Degott C, Rueff B, Santoni P, Bacteroides bacteremia of undetermined origin: strong association with portal vein thrombosis and cryptogenic pylephlebitis. Eur J Gastroenterol Hepatol 1993; 5: 655– 659.
  32. [33]Grendell JH, Ockner RK. Mesenteric venous thrombosis. Gastroenterology 1982; 82: 358– 372. 7033036
  33. [34]Sheen CL, Lamparelli H, Milne A, Green I, Ramage JK. Clinical features, diagnosis and outcome of acute portal vein thrombosis. Q J Med 2000; 93: 531– 534. 10924535
  34. [35]Clavien PA. Diagnosis and management of mesenteric infarction. Br J Surg 1990; 77: 601– 603. 2200547
  35. [36]Valla DC, Condat B. Portal vein thrombosis in adults: pathophysiology, pathogenesis and management. J Hepatol 2000; 32: 865– 871. 10845677
  36. [37]Kumar S, Sarr M, Kamath PS. Mesenteric venous thrombosis. N Engl J Med 2001; 345: 1683– 1688. 11759648
  37. [38]Dourakis SP, Tsochatzis E, Alexopoulou A, Archimandritis AJ. Pylephlebitis complicating silent diverticulitis. Lancet 2006; 368: 422. 16876671
  38. [39]Haddad MC, Clark DC, Sharif HS, al Shahed M, Aideyan O, Sammak BM. MR, CT, and ultrasonography of splanchnic venous thrombosis. Gastrointest Radiol 1992; 17: 34– 40. 1544556
  39. [40]Kreft B, Strunk H, Flacke S, Wolff M, Conrad R, Gieseke J, Detection of thrombosis in the portal venous system: comparison of contrast-enhanced MR angiography with intraarterial digital subtraction angiography. Radiology 2000; 216: 86– 92. 10887231
  40. [41]Rahmouni A, Mathieu D, Golli M, Douek P, Anglade MC, Caillet H, Value of CT and sonography in the conservative management of acute splenoportal and superior mesenteric venous thrombosis. Gastrointest Radiol 1992; 17: 135– 140. 1551509
  41. [42]Tessler FN, Gehring BJ, Gomes AS, Perrella RR, Ragavendra N, Busuttil RW, Diagnosis of portal vein thrombosis: value of color Doppler imaging. AJR Am J Roentgenol 1991; 157: 293– 296. 1853809
  42. [43]Wiersema MJ, Chak A, Kopecky KK, Wiersema LM. Duplex Doppler endosonography in the diagnosis of splenic vein, portal vein, and portosystemic shunt thrombosis. Gastrointest Endosc 1995; 42: 19– 26. 7557171
  43. [44]Van Gansbeke D, Avni EF, Delcour C, Engelholm L, Struyven J. Sonographic features of portal vein thrombosis. AJR Am J Roentgenol 1985; 144: 749– 752. 3883708
  44. [45]Bach AM, Hann LE, Brown KT, Getrajdman GI, Herman SK, Fong Y, Portal vein evaluation with US: comparison to angiography combined with CT arterial portography. Radiology 1996; 201: 149– 154. 8816536
  45. [46]Mathieu D, Vasile N, Grenier P. Portal thrombosis: dynamic CT features and course. Radiology 1985; 154: 737– 741. 3881793
  46. [47]Chou CK, Mak CW, Tzeng WS, Chang JM. CT of small bowel ischemia. Abdom Imaging 2004; 29: 18– 22. 15160748
  47. [48]Cerri GG, Habr-Gama A, Paranagua-Vezozzo D, Machado MC, Pinotti HW, Magalhaes A. Doppler demonstration of cystic vein dilatation secondary to portal vein thrombosis. Surg Endosc 1991; 5: 92– 93. 1948622
  48. [49]Baril N, Wren S, Radin R, Ralls P, Stain S. The role of anticoagulation in pylephlebitis. Am J Surg 1996; 172: 449– 452; discussion 452–443. 8942542
  49. [50]Bates SM, Ginsberg JS. Clinical practice. Treatment of deep-vein thrombosis. N Engl J Med 2004; 351: 268– 277. 15254285
  50. [51]Hassn AM, Al-Fallouji MA, Ouf TI, Saad R. Portal vein thrombosis following splenectomy. Br J Surg 2000; 87: 362– 373. 10718950
  51. [52]Lagasse JP, Bahallah ML, Salem N, Debillon G, Labarriere D, Serve MP, Acute thrombosis of the portal system. Treatment with alteplase and heparin or with heparin alone in 10 patients. [in French] Gastroenterol Clin Biol 1997; 21: 919– 923. 9587554
  52. [53]de Franchis R Evolving consensus in portal hypertension. Report of the Baveno IV consensus workshop on methodology of diagnosis and therapy in portal hypertension. J Hepatol 2005; 43: 167– 176. 15925423
  53. [54]Prandoni P, Lensing AWA, Prins MH, Bernardi E, Marchiori A, Bagatella P, Residual venous thrombosis as a predictive factor of recurrent venous thromboembolism. Ann Intern Med 2002; 137: 955– 960. 12484710
  54. [56]Malkowski P, Pawlak J, Michalowicz B, Szczerban J, Wroblewski T, Leowska E, Thrombolytic treatment of portal thrombosis. Hepatogastroenterology 2003; 50: 2098– 2100. 14696472
  55. [57]Grisham A, Lohr J, Guenther JM, Engel AM. Deciphering mesenteric venous thrombosis: imaging and treatment. Vasc Endovascular Surg 2005; 39: 473– 479. 16382268
  56. [58]Brunaud L, Antunes L, Collinet-Adler S, Marchal F, Ayav A, Bresler L, Acute mesenteric venous thrombosis: case for nonoperative management. J Vasc Surg 2001; 34: 673– 679. 11668323
  57. [59]Abdu RA, Zakhour BJ, Dallis DJ. Mesenteric venous thrombosis–1911 to 1984. Surgery 1987; 101: 383– 388. 3563882
  58. [60]Joh JH, Kim DI. Mesenteric and portal vein thrombosis: treated with early initiation of anticoagulation. Eur J Vasc Endovasc Surg 2005; 29: 204– 208. 15649730
  59. [61]Eugene C, Valla D, Wesenfelder L, Fingerhut A, Bergue A, Merrer J, Small intestinal stricture complicating superior mesenteric vein thrombosis. A study of three cases. Gut 1995; 37: 292– 295. 7557585 PMC1382735
  60. [62]Condat B, Vilgrain V, Asselah T, O’Toole D, Rufat P, Zappa M, Portal cavernoma-associated cholangiopathy: a clinical and MR cholangiography coupled with MR portography imaging study. Hepatology 2003; 37: 1302– 1308. 12774008
  61. [63]Khuroo MS, Yattoo GN, Zargar SA, Javid G, Dar MY, Khan BA, Biliary abnormalities associated with extrahepatic portal venous obstruction. Hepatology 1993; 17: 807– 813. 8491448
  62. [64]Condat B, Pessione F, Hillaire S, Denninger MH, Guillin MC, Poliquin M, Current outcome of portal vein thrombosis in adults: risk and benefit of anticoagulant therapy. Gastroenterology 2001; 120: 490– 497. 11159889
  63. [65]Minguez B, Garcia-Pagan JC, Bosch J, Turnes J, Alonso J, Rovira A, Noncirrhotic portal vein thrombosis exhibits neuropsychological and MR changes consistent with minimal hepatic encephalopathy. Hepatology 2006; 43: 707– 714. 16557541
  64. [66]Gupta D, Vijaya DR, Gupta R, Dhiman RK, Bhargava M, Verma J, Prevalence of hepatopulmonary syndrome in cirrhosis and extrahepatic portal venous obstruction. Am J Gastroenterol 2001; 96: 3395– 3399. 11774955
  65. [67]Ueno N, Sasaki A, Tomiyama T, Tano S, Kimura K. Color Doppler ultrasonography in the diagnosis of cavernous transformation of the portal vein. J Clin Ultrasound 1997; 25: 227– 233. 9314103
  66. [68]Dumortier J, Vaillant E, Boillot O, Poncet G, Henry L, Scoazec JY, Diagnosis and treatment of biliary obstruction caused by portal cavernoma. Endoscopy 2003; 35: 446– 450. 12701019
  67. [69]Palazzo L, Hochain P, Helmer C, Cuillerier E, Landi B, Roseau G, Biliary varices on endoscopic ultrasonography: clinical presentation and outcome. Endoscopy 2000; 32: 520– 524. 10917183
  68. [70]Garcia-Tsao G, Sanyal AJ, Grace ND, Carey W. Prevention and management of gastroesophageal varices and variceal hemorrhage in cirrhosis. Hepatology 2007; 46: 322– 338. 17879356
  69. [71]Orr DW, Harrisson PM, Karani J, Rela M, Heaton ND, O’Grady JG, Chronic portomesenteric and portosplenomesenteric venous thrombosis: evaluation of long term follow-up and determinants of survival [Abstract]. Hepatology 2005; 42: 212A.
  70. [72]Kahn D, Krige JE, Terblanche J, Bornman PC, Robson SC. A 15-year experience of injection sclerotherapy in adult patients with extrahepatic portal venous obstruction. Ann Surg 1994; 219: 34– 39. 8297173 PMC1243087
  71. [73]Vleggaar FP, van Buuren HR, Schalm SW. Endoscopic sclerotherapy for bleeding oesophagogastric varices secondary to extrahepatic portal vein obstruction in an adult Caucasian population. Eur J Gastroenterol Hepatol 1998; 10: 81– 85. 9512958
  72. [74]Orloff MJ, Orloff MS, Girard B, Orloff SL. Bleeding esophagogastric varices from extrahepatic portal hypertension: 40 years’ experience with portal-systemic shunt. J Am Coll Surg 2002; 194: 717– 728; discussion 728–730. 12081062
  73. [75]Warren WD, Henderson JM, Millikan WJ, Galambos JT, Bryan FC. Management of variceal bleeding in patients with noncirrhotic portal vein thrombosis. Ann Surg 1988; 207: 623– 634. 3259859 PMC1493505
  74. [76]Senzolo M, Tibbals J, Cholongitas E, Triantos CK, Burroughs AK, Patch D. Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with and without cavernous transformation. Aliment Pharmacol Ther 2006; 23: 767– 775. 16556179
  75. [77]Kitchens CS, Weidner MH, Lottenberg R. Chronic oral anticoagulant therapy for extrahepatic visceral thrombosis is safe. J Thromb Thrombolysis 2007; 23: 223– 228. 17221331
  76. [78]Chaudhary A, Dhar P, Sarin SK, Sachdev A, Agarwal AK, Vij JC, Bile duct obstruction due to portal biliopathy in extrahepatic portal hypertension: surgical management. Br J Surg 1998; 85: 326– 329. 9529484
  77. [79]Sarin SK, Sollano JD, Chawla YK, Amarapurkar D, Hamid S, Hashizume M, Consensus on extra-hepatic portal vein obstruction. Liver Int 2006; 26: 512– 519. 16761994
  78. [80]Shinohara T, Ando H, Watanabe Y, Seo T, Harada T, Kaneko K. Extrahepatic portal vein morphology in children with extrahepatic portal hypertension assessed by 3-dimensional computed tomographic portography: a new etiology of extrahepatic portal hypertension. J Pediatr Surg 2006; 41: 812– 816. 16567199
  79. [81]Balta G, Altay C, Gurgey A. PAI-1 gene 4G/5G genotype: A risk factor for thrombosis in vessels of internal organs. Am J Hematol 2002; 71: 89– 93. 12353306
  80. [82]Dubuisson C, Boyer-Neumann C, Wolf M, Meyer D, Bernard O. Protein C, protein S and antithrombin III in children with portal vein obstruction. J Hepatol 1997; 27: 132– 135. 9252086
  81. [83]El-Karaksy H, El-Koofy N, El-Hawary M, Mostafa A, Aziz M, El-Shabrawi M, Prevalence of factor V Leiden mutation and other hereditary thrombophilic factors in Egyptian children with portal vein thrombosis: results of a single-center case-control study. Ann Hematol 2004; 83: 712– 715. 15309526
  82. [84]Heller C, Schobess R, Kurnik K, Junker R, Gunther G, Kreuz W, Abdominal venous thrombosis in neonates and infants: role of prothrombotic risk factors - a multicentre case-control study. For the Childhood Thrombophilia Study Group. BrJ Haematol 2000; 111: 534– 539. 11122096
  83. [85]Pinto RB, Silveira TR, Rosling L, Bandinelli E. Thrombophilic disorders in children and adolescents with portal vein thrombosis. [in Portugese] J Pediatr (Rio J) 2003; 79: 165– 172. 14502338
  84. [86]Yachha SK, Aggarwal R, Sharma BC, Misra RN, Aggarwal A, Naik SR. Functional protein C and anti-cardiolipin antibody in children with portal vein thrombosis. Indian J Gastroenterol 2001; 20: 47– 49. 11305488
  85. [87]Mack CL, Superina RA, Whitington PF. Surgical restoration of portal flow corrects procoagulant and anticoagulant deficiencies associated with extrahepatic portal vein thrombosis. J Pediatr 2003; 142: 197– 199. 12584545
  86. [88]Morag I, Epelman M, Daneman A, Moineddin R, Parvez B, Shechter T, Portal vein thrombosis in the neonate: risk factors, course, and outcome. J Pediatr 2006; 148: 735– 739. 16769378
  87. [89]Bellomo-Brandao MA, Morcillo AM, Hessel G, Cardoso SR, Servidoni Mde F, da-Costa-Pinto EA. Growth assessment in children with extra-hepatic portal vein obstruction and portal hypertension. Arq Gastroenterol 2003; 40: 247– 250. 15264047
  88. [90]Zargar SA, Javid G, Khan BA, Yattoo GN, Shah AH, Gulzar GM, Endoscopic ligation compared with sclerotherapy for bleeding esophageal varices in children with extrahepatic portal venous obstruction. Hepatology 2002; 36: 666– 672. 12198659
  89. [91]Pande GK, Reddy VM, Kar P, Sahni P, Berry M, Tandon BN, Operations for portal hypertension due to extrahepatic obstruction: results and 10 year follow up. Br Med J (Clin Res Ed) 1987; 295: 1115– 1117. PMC1248187 3120906
  90. [92]Superina R, Bambini DA, Lokar J, Rigsby C, Whitington PF. Correction of extrahepaticportalvein thrombosis bythe mesenteric to leftportalvein bypass. Ann Surg 2006; 243: 515– 521. 16552203 PMC1448975
  91. [93]Okuda K, Ohnishi K, Kimura K, Matsutani S, Sumida M, Goto N, Incidence of portal vein thrombosis in liver cirrhosis. An angiographic study in 708 patients. Gastroenterology 1985; 89: 279– 286. 4007419
  92. [94]Francoz C, Belghiti J, Vilgrain V, Sommacale D, Paradis V, Condat B, Splanchnic vein thrombosis in candidates for liver transplantation: usefulness of screening and anticoagulation. Gut 2005; 54: 691– 697. 15831918 PMC1774501
  93. [95]Tublin ME, Dodd GD 3rd, Baron RL. Benign and malignantportal vein thrombosis: differentiation by CT characteristics. AJR Am J Roentgenol 1997; 168: 719– 723. 9057522
  94. [96]Rossi S, Rosa L, Ravetta V, Cascina A, Quaretti P, Azzaretti A, Contrast-enhanced versus conventional and color Doppler sonography for the detection of thrombosis of the portal and hepatic venous systems. AJR Am J Roentgenol 2006; 186: 763– 773. 16498104
  95. [97]Nonami T, Yokoyama I, Iwatsuki S, Starzl TE. The incidence of portal vein thrombosis at liver transplantation. Hepatology 1992; 16: 1195– 1198. 1427658 PMC2989675
  96. [98]Amitrano L, Brancaccio V, Guardascione MA, Margaglione M, Iannaccone L, D’Andrea G, Inherited coagulation disorders in cirrhotic patients with portal vein thrombosis. Hepatology 2000; 31: 345– 348. 10655256
  97. [99]Amitrano L, Brancaccio V, Guardascione MA, Margaglione M, Sacco M, Martino R, Portal vein thrombosis after variceal endoscopic sclerotherapy in cirrhotic patients: role of genetic thrombophilia. Endoscopy 2002; 34: 535– 538. 12170404
  98. [100]Cavallari A, Vivarelli M, Bellusci R, Jovine E, Mazziotti A, Rossi C. Treatment of vascular complications following liver transplantation: multidisciplinary approach. Hepatogastroenterology 2001; 48: 179– 183. 11268960
  99. [101]Settmacher U, Nussler NC, Glanemann M, Haase R, Heise M, Bechstein WO, Venous complications after orthotopic liver transplantation. Clin Transplant 2000; 14: 235– 241. 10831082
  100. [102]Shulman HM, Fisher LB, Schoch HG, Henne KW, McDonald GB. Venoocclusive disease of the liver after marrow transplantation: histological correlates of clinical signs and symptoms. Hepatology 1994; 19: 1171– 1180. 8175139
  101. [103]DeLeve LD, Wang X, Kuhlenkamp JF, Kaplowitz N. Toxicity of azathio-prine and monocrotaline in murine sinusoidal endothelial cells and hepatocytes: the role of glutathione and relevance to hepatic venooclusive disease. Hepatology 1996; 23: 589– 599. 8617441
  102. [104]DeLeve LD, Ito I, Bethea NW, McCuskey MK, Wang X, McCuskey RS. Embolization by sinusoidal lining cell obstructs the microcirculation in rat sinusoidal obstruction syndrome. Am J Physiol Gastrointest Liver Physiol 2003; 284: G1045– G1052. 12584111
  103. [105]McDonald GB, Hinds MS, Fisher LD, Schoch HG, Wolford JL, Banaji M, Veno-occlusive disease of the liver and multiorgan failure after bone marrow transplantation - a cohort study of 355 patients. Ann Intern Med 1993; 118: 255– 267. 8420443
  104. [106]Lee JL, Gooley T, Bensinger W, Schiffman K, McDonald GB. Veno-occlusive disease of the liver after busulfan, melphalan, and thiotepa conditioning therapy: incidence, risk factors, and outcome. Biol Blood Marrow Transplant 1999; 5: 306– 315. 10534061
  105. [107]Carreras E, Rosinol L, Terol MJ, Alegre A, de Arriba F, Garcia-Larana J, Veno-occlusive disease of the liver after high-dose cytoreductive therapy with busulfan and melphalan for autologous blood stem cell transplantation in multiple myelomapatients. Biol Blood Marrow Transplant 2007; 13: 1448– 1454. 18022574
  106. [108]McDonald GB. Liver disease of uncertain cause. Bone Marrow Transplant 2004; 33: 977– 978. 15129235
  107. [109]Jones RJ, Lee KS, Beschorner WE, Vogel VG, Grochow LB, Braine HG, Venoocclusive disease of the liver following bone marrow transplantation. Transplantation 1987; 44: 778– 783. 3321587
  108. [110]Blostein MD, Paltiel OB, Thibault A, Rybka WB. A comparison of clinical criteria for the diagnosis of veno-occlusive disease of the liver after bone marrow transplantation. Bone Marrow Transplant 1992; 10: 439– 443. 1464007
  109. [111]Hommeyer SC, Teefey SA, Jacobson AF, Higano CS, Bianco JA, Colacurcio CJ, Venocclusive disease of the liver: prospective study of US evaluation. Radiology 1992; 184: 683– 686. 1509050
  110. [112]Teefey SA, Brink JA, Borson RA, Middleton WD. Diagnosis of venoocclusive disease of the liver after bone marrow transplantation: value of duplex sonography. Am J Roentgenol 1995; 164: 1397– 1401. 7754881
  111. [113]McCarville MB, Hoffer FA, Howard SC, Goloubeva O, Kauffman WM. Hepatic veno-occlusive disease in children undergoing bone-marrow transplantation: usefulness of sonographic findings. Pediatr Radiol 2001; 31: 102– 105. 11214676
  112. [114]Lassau N, Leclere J, Auperin A, Bourhis JH, Hartmann O, Valteau-Couanet D, Hepatic veno-occlusive disease after myeloablative treatment and bone marrow transplantation: value of gray-scale and Doppler US in 100 patients. Radiology 1997; 204: 545– 552. 9240551
  113. [115]Lassau N, Auperin A, Leclere J, Bennaceur A, Valteau-Couanet D, Hartmann O. Prognostic value of doppler-ultrasonography in hepatic veno-occlusive disease. Transplantation 2002; 74: 60– 66. 12134100
  114. [116]Shulman HM, Gooley T, Dudley MD, Kofler T, Feldman R, Dwyer D, Utility of transvenous liver biopsies and wedged hepatic venous pressure measurements in sixty marrow transplant recipients. Transplantation 1995; 59: 1015– 1022. 7709437
  115. [117]Carreras E, Granena A, Navasa M, Bruguera M, Marco V, Sierra J, Transjugular liver biopsy in BMT. Bone Marrow Transplant 1993; 11: 21– 26. 8431707
  116. [118]Bearman SI, Anderson GL, Mori M, Hinds MS, Shulman HM, McDonald GB. Venoocclusive disease of the liver: development of a model for predicting fatal outcome after marrow transplantation. J Clin Oncol 1993; 11: 1729– 1736. 8355040
  117. [119]McDonald GB, Sharma P, Matthews DE, Shulman HM, Thomas ED. The clinical course of 53 patients with venocclusive disease of the liver after marrow transplantation. Transplantation 1985; 36: 603– 608. 3890288
  118. [120]Carreras E, Bertz H, Arcese W, Vernant JP, Tomas JF, Hagglund H, Incidence and outcome of hepatic veno-occlusive disease after blood or marrow transplantation: a prospective cohort study of the European Group for Blood and Marrow Transplantation. European Group for Blood and Marrow Transplantation Chronic Leukemia Working Party. Blood 1998; 92: 3599– 3604. 9808553
  119. [121]Ganem G, Saint-Marc Girardin MF, Kuentz M, Cordonnier C, Morinello G, Teboul C, Venocclusive disease of the liver after allogeneic bone marrow transplantation in man. Int J Radiat Oncol Biol Phys 1988; 14: 879– 884. 3283084
  120. [122]Hasegawa S, Horibe K, Kawabe T, Kato K, Kojima S, Matsuyama T, Veno-occlusive disease of the liver after allogeneic bone marrow transplantation in children with hematologic malignancies: incidence, onset time and risk factors. Bone Marrow Transplant 1998; 22: 1191– 1197. 9894723
  121. [123]McDermott WV, Stone MD, Bothe A Jr, Trey C. Budd-Chiari syndrome. Historical and clinical review with an analysis of surgical corrective procedures. Am J Surg 1984; 147: 463– 467. 6324603
  122. [124]Wadleigh M, Richardson PG, Zahrieh D, Lee SJ, Cutler C, Ho V, Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood 2003; 102: 1578– 1582. 12738663
  123. [125]Dulley FL, Kanfer EJ, Appelbaum FR, Amos D, Hill RS, Buckner CD, Venocclusive disease of the liver after chemoradiotherapy and autologous bone marrow transplantation. Transplantation 1987; 43: 870– 873. 3296355
  124. [126]Reiss U, Cowan M, McMillan A, Horn B. Hepatic venoocclusive disease in blood and bone marrow transplantation in children and young adults: incidence, risk factors, and outcome in a cohort of 241 patients. J Pediatr Hematol Oncol 2002; 24: 746– 750. 12468917
  125. [127]Frickhofen N, Wiesneth M, Jainta C, Hertenstein B, Heymer B, Bianchi L, Hepatitis C virus infection is a risk factor for liver failure from veno-occlusive disease after bone marrow transplantation. Blood 1994; 83: 1998– 2004. 7511444
  126. [128]Strasser SI, Myerson D, Spurgeon CL, Sullivan KM, Storer B, Schoch HG, Hepatitis C virus infection and bone marrow transplantation: a cohort study with 10-year follow-up. Hepatology 1999; 29: 1893– 1899. 10347135
  127. [129]Cordonnier C, Maury S, Esperou H, Pautas C, Beaune J, Rodet M, Do minitransplants have minicosts? A cost comparison between myeloa-blative and nonmyeloablative allogeneic stem cell transplant in patients with acute myeloid leukemia. Bone Marrow Transplant 2005; 36: 649– 654. 16044135
  128. [130]Hogan WJ, Maris M, Storer B, Sandmaier BM, Maloney DG, Schoch HG, Hepatic injury after nonmyeloablative conditioning followed by allogeneic hematopoietic cell transplantation: a study of 193 patients. Blood 2004; 103: 78– 84. 12969980
  129. [131]Clift RA, Buckner CD, Appelbaum FR, Bearman SI, Petersen FB, Fisher LD, Allogeneic marrow transplantation in patients with acute myeloid leukemia in first remission: a randomized trial of two irradiation regimens. Blood 1990; 76: 1867– 1871. 2224134
  130. [132]DeLeve LD. Cellular target of cyclophosphamide toxicity in the murine liver: role of glutathione and site of metabolic activation. Hepatology 1996; 24: 830– 837. 8855185
  131. [133]McDonald GB, Slattery JT, Bouvier ME, Ren S, Batchelder AL, Kalhorn TF, Cyclophosphamide metabolism, liver toxicity, and mortality following hematopoietic stem cell transplantation. Blood 2003; 101: 2043– 2048. 12406916
  132. [134]McDonald GB, McCune JS, Batchelder A, Cole SL, Phillips B, Ren AG, Metabolism-based cyclophosphamide dosing for hematopoietic cell transplant. Clin Pharmacol Ther 2005; 78: 298– 308. 16153400
  133. [135]Salinger DH, McCune JS, Ren AG, Shen DD, Slattery JT, Phillips B, Real-time dose adjustment of cyclophosphamide in a preparative regimen for hematopoietic cell transplant: a Bayesian pharmacokinetic approach. Clin Cancer Res 2006; 12: 4888– 4898. 16914577
  134. [136]Grochow LB. Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens. Semin Oncol 1993; 20: 18– 25. 8342071
  135. [137]Demirer T, Buckner CD, Appelbaum FR, Bensinger WI, Sanders J, Lambert K, Busulfan, cyclophosphamide and fractionated total body irradiation for autologous or syngeneic marrow transplantation for acute and chronic myelogenous leukemia: phase I dose escalation of busulfan based on targeted plasma levels. Bone Marrow Transplant 1996; 17: 491– 495. 8722344
  136. [138]Vaughan WP, Carey D, Perry S, Westfall AO, Salzman DE. A limited sample strategy for pharmacokinetic therapy with intravenous busulfan. Biol Blood Marrow Transplant 2002; 8: 619– 624. 12463481
  137. [139]Hassan M, Ehrsson H, Ljungman P. Aspects concerning busulfan pharmacokinetics and bioavailability. Leuk Lymphoma 1996; 22: 395– 407. 8882952
  138. [140]Méresse V, Hartmann O, Vassal G, Benhamou E, Valteau-Couanet D, Brugieres L, Risk factors for hepatic veno-occlusive disease after high-dose busulfan-containing regimens followed by autologous bone marrow transplantation: a study in 136 children. Bone Marrow Transplant 1992; 10: 135– 141. 1525602
  139. [141]Shimoni A, Bielorai B, Toren A, Hardan I, Avigdor A, Yeshuran, Intravenous busulfan-based conditioning prior to allogeneic hematopoietic stem cell transplantation: myeloablation with reduced toxicity. Exp Hematol 2003; 31: 428– 434. 12763142
  140. [142]Lee J-H, Choi S-J, Lee J-H, Kim S-E, Park C-J, Chi H-S, Decreased incidence of hepatic veno-occlusive disease and fewer hemostatic derangements associated with intravenous busulfan vs oral busulfan in adults conditioned with busulfan + cyclophosphamide for allogeneic bone marrow transplantation. Ann Hematol 2005; 84: 321– 330. 15580502
  141. [143]Kashyap A, Wingard J, Cagnoni P, Roy J, Tarantolo S, Hu W, Intravenous versus oral busulfan as part of a busulfan/cyclophosphamide preparative regimen for allogeneic hematopoietic stem cell transplantation: decreased incidence of hepatic venoocclusive disease (HVOD), HVOD-related mortality, and overall 100-day mortality. Biol Blood Marrow Transplant 2002; 8: 493– 500. 12374454
  142. [144]Grochow LB, Jones RJ, Brundrett RB, Braine HG, Chen TL, Saral R, Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol 1989; 25: 55– 61. 2591002
  143. [145]Bleyzac N, Souillet G, Magron P, Janoly A, Martin P, Bertrand Y, Improved clinical outcome of paediatric bone marrow recipients using a test dose and Bayesian pharmacokinetic individualization of busulfan dosage regimens. Bone Marrow Transplant 2001; 28: 743– 751. 11781625
  144. [146]Schuler US, Ehrsam M, Schneider A, Schmidt H, Deeg J, Ehninger G. Pharmacokinetics of intravenous busulfan and evaluation of the bioavailability of the oral formulation in conditioning for haematopoietic stem cell transplantation. Bone Marrow Transplant 1998; 22: 241– 244. 9720736
  145. [147]Slattery JT, Clift RA, Buckner CD, Radich J, Storer B, Bensinger WI, Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood 1997; 89: 3055– 3060. 9108427
  146. [148]Zwaveling J, Bredius RGM, Cremers SCLM, Ball LM, Lankester AC, Teepe-Twiss IM, Intravenous busulfan in children prior to stem cell transplantation: study of pharmacokinetics in association with early clinical outcome and toxicity. Bone Marrow Transplant 2005; 35: 17– 23. 15502853
  147. [149]Bornhauser M, Storer B, Slattery JT, Appelbaum FR, Deeg HJ, Hansen J, Conditioning with fludarabine and targeted busulfan for transplantation of allogeneic hematopoietic stem cells. Blood 2003; 102: 820– 826. 12676781
  148. [150]DeLima M, Ghaddar H, Pierce S, Estey E. Treatmentof newly-diagnosed acute myelogenous leukaemia in patients aged 80 years and above. Br J Haematol 1996; 93: 89– 95. 8611481
  149. [151]Hagglund H, Remberger M, Klaesson S, Lonnqvist B, Ljungman P, Ringden O. Norethisterone treatment, a major risk-factor for veno-occlusive disease in the liver after allogeneic bone marrow transplantation. Blood 1998; 92: 4568– 4572. 9845522
  150. [152]Attal M, Huguet F, Ruble H, Charlet JP, Schlaifer D, Huynh A, Prevention of regimen-related toxicities after bone marrow transplantation by pentoxifylline - a prospective, randomized trial. Blood 1993; 82: 732– 736. 8338943
  151. [153]Rosenthal J, Sender L, Secola R, Killen R, Millerick M, Murphy L, Phase II trial of heparin prophylaxis for veno-occlusive disease of the liver in children undergoing bone marrow transplantation. Bone Marrow Transplant 1996; 18: 185– 191. 8832013
  152. [154]Bearman SI, Hinds MS, Wolford JL, Petersen FB, Nugent DL, Slichter SJ, A pilot study of continuous infusion heparin for the prevention of hepatic veno-occlusive disease after bone marrow transplantation. Bone Marrow Transplant 1990; 5: 407– 411. 2369681
  153. [155]Marsa-Vila L, Gorin NC, Laporte JP, Labopin M, Dupuy-Montbrun MC, Fouillard L, Prophylactic heparin does not prevent liver veno-occlusive disease following autologous bone marrow transplantation. Eur J Haematol 1991; 47: 346– 354. 1761121
  154. [156]Imran H, Tleyjeh IM, Zirakzadeh A, Rodriguez V, Khan SP. Use of prophylactic anticoagulation and the risk of hepatic veno-occlusive disease in patients undergoing hematopoietic stem cell transplantation: a systematic review and meta-analysis. Bone Marrow Transplant 2006; 37: 677– 686. 16489362
  155. [157]Essell JH, Schroeder MT, Harman GS, Halvorson R, Lew V, Callander N, Ursodiol prophylaxis against hepatic complications of allogeneic bone marrow transplantation. A randomized, double-blind, placebo-controlled trial. Ann Intern Med 1998; 128: 975– 981. 9625683
  156. [158]Ohashi K, Tanabe J, Watanabe R, Tanaka T, Sakamaki H, Maruta A, The Japanese multicenter open randomized trial of ursodeoxycholic acid prophylaxis for hepatic veno-occlusive disease after stem cell transplantation. Am J Hematol 2000; 64: 32– 38. 10815785
  157. [159]Ruutu T, Eriksson B, Remes K, Juvonen E, Volin L, Remberger M, Ursodeoxycholic acid for the prevention of hepatic complications in allogeneic stem cell transplantation. Blood 2002; 100: 1977– 1983. 12200355
  158. [160]Park SH, Lee MH, Lee H, Kim HS, Kim K, Kim WS, Arandomized trial of heparin plus ursodiol vs. heparin alone to prevent hepatic veno-occlusive disease after hematopoietic stem cell transplantation. Bone Marrow Transplant 2002; 29: 137– 143. 11850708
  159. [161]Tay J, Tinmouth A, Fergusson D, Huebsch L, Allan DS. Systematic review of controlled clinical trials on the use of ursodeoxycholic acid for the prevention of hepatic veno-occlusive disease in hematopoietic stem cell transplantation. Biol Blood Marrow Transplant 2007; 13: 206– 217. 17241926
  160. [162]Gluckman E, Jolivet I, Scrobohaci ML, Devergie A, Traineau R, Bourdeau-Esperou H, Role of PGE1 to prevent veno-occlusive disease of the liver after bone marrow transplantation. Nouv Rev Fr Hematol 1990; 32: 1– 3. 2349075
  161. [163]Bearman SI, Shen DD, Hinds MS, Hill HA, McDonald GB. A phase-I phase-II study of prostaglandin E1 for the prevention of hepatic venoocclusive disease after bone marrow transplantation. Br J Haematol 1993; 84: 724– 730. 8217833
  162. [164]Clift RA, Bianco JA, Appelbaum FR, Buckner CD, Singer JW, Bakke L, A randomized controlled trial of pentoxifylline for the prevention of regimen-related toxicities in patients undergoing allogeneic marrow transplantation. Blood 1993; 82: 2025– 2030. 8400255
  163. [165]Barkholt L, Remberger M, Hassan Z, Fransson K, Omazic B, Svahn BM, A prospective randomized study using N-acetyl-L-cysteine for early liver toxicity after allogeneic hematopoietic stem cell transplantation. Bone Marrow Transplant 2008; 41: 785– 790. 18176610
  164. [166]Bearman SI, Lee JL, Baron AE, McDonald GB. Treatment of hepatic venocclusive disease with recombinant human tissue plasminogen activator and heparin in 42 marrow transplant patients. Blood 1997; 89: 1501– 1506. 9057629
  165. [167]Kulkarni S, Rodriguez M, Lafuente A, Mateos P, Mehta J, Singhal S, Recombinant tissue plasminogen activator (rtPA) for the treatment of hepatic veno-occlusive disease (VOD). Bone Marrow Transplant 1999; 23: 803– 807. 10231143
  166. [168]Hagglund H, Ringden O, Ljungman P, Winiarski J, Ericzon B, Tyden G. No beneficial effects, but severe side effects caused by recombinant human tissue plasminogen activator for treatment of hepatic veno-occlusive disease after allogeneic bone marrow transplantation. Transplant Proc 1995; 27: 3535. 8540088
  167. [169]Hagglund H, Ringden O, Ericzon BG, Duraj F, Ljungman P, Lonnqvist B, Treatment of hepatic venoocclusive disease with recombinant human tissue plasminogen activator or orthotopic liver transplantation after allogeneic bone marrow transplantation. Transplantation 1996; 62: 1076– 1080. 8900305
  168. [170]Hohlfeld T, Strobach H, Schror K. Stimulation of prostacyclin synthesis by defibrotide: improved contractile recovery from myocardial “stunning”. J Cardiovasc Pharmacol 1991; 17: 108– 115. 1708043
  169. [171]Biagi G, Legnani C, Rodorigo G, Coccheri S. Modulation of arachidonate metabolite generation in human blood by oral defibrotide. Arzne-imittelforschung 1991; 41: 511– 514. 1654908
  170. [172]San T, Moini H, Emerk K, Bilsel S. Protective effect of defibrotide on perfusion induced endothelial damage. Thromb Res 2000; 99: 335– 341. 10963784
  171. [173]Masini E, Lupini M, Mugnai L, Raspanti S, Mannaioni PF. Polydeoxyri-bonucleotides and nitric oxide release from guinea-pig hearts during ischaemia and reperfusion. Br J Pharmacol 1995; 115: 629– 635. 7582482 PMC1908494
  172. [174]Berti F, Rossoni G, Della Bella D, Villa LM, Buschi A, Trento F, Nitric oxide and prostacyclin influence coronary vasomotor tone in perfused rabbit heart and modulate endothelin-1 activity. J Cardiovasc Pharmacol 1993; 22: 321– 326. 7692176
  173. [175]Pellegatta F, Lu Y, Radaelli A, Zocchi MR, Ferrero E, Chierchia S, Drug-induced in vitro inhibition of neutrophil-endothelial cell adhesion. Br J Pharmacol 1996; 118: 471– 476. 8762067 PMC1909737
  174. [176]Klocking HP. Acute t-PA release by defibrotide. Thromb Res 1992; 66: 779– 785. 1519236
  175. [177]Bianchi G, Barone D, Lanzarotti E, Tettamanti R, Porta R, Moltrasio D, Defibrotide, a single-stranded polydeoxyribonucleotide acting as an adenosine receptor agonist. Eur J Pharmacol 1993; 238: 327– 334. 8405101
  176. [178]Abbate R, Gori AM, Martini F, Attanasio M, Comeglio, Giusti B, Defibrotide reduces monocyte PAI-2 and procoagulant activity. Semin Thromb Hemost 1995; 21: 245– 250. 7660147
  177. [179]Falanga A, Vignoli A, Marchetti M, Barbui T. Defibrotide reduces procoagulant activity and increases fibrinolytic properties of endothelial cells. Leukemia 2003; 17: 1636– 1642. 12886253
  178. [180]Lefer AM, Aoki N, Mulloy D. Coronary endothelium-protective effects of defibrotide in ischaemia and reperfusion. Naunyn Schmiedebergs Arch Pharmakol 1990; 341: 246– 250. 2160617
  179. [181]Richardson PG, Elias AD, Krishnan A, Wheeler C, Nath R, Hoppen-steadt D, Treatment of severe veno-occlusive disease with defib-rotide: compassionate use results in response without significant toxicity in a high-risk population. Blood 1998; 92: 737– 744. 9680339
  180. [182]Chopra R, Eaton JD, Grass! A, Potter M, Shaw B, Salat C, Defib-rotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study. Br J Haematol 2000; 111: 1122– 1129. 11167751
  181. [183]Richardson PG, Murakami C, Jin Z, Warren D, Momtaz P, Hoppensteadt D, Multi-institutional use of defibrotide in 88 patients after stem cell transplantation with severe veno-occlusive disease and multisystem organ failure: response without significant toxicity in a high-risk population and factors predictive of outcome. Blood 2002; 100: 4337– 4343. 12393437
  182. [184]Chalandon Y, Roosnek E, Mermillod B, Newton A, Ozsahin H, Wacker P, Prevention of veno-occlusive disease with defibrotide after allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2004; 10: 347– 354. 15111934
  183. [185]Corbacioglu S, Greil J, Peters C, Wulffraat N, Laws HJ, Dilloo D, Defibrotide in the treatment of children with veno-occlusive disease (VOD): a retrospective multicentre study demonstrates therapeutic efficacy upon early intervention. Bone Marrow Transplant 2004; 33: 189– 195. 14661036
  184. [186]Fried MW, Connaghan DG, Sharma S, Martin LG, Devine S, Holland K, Transjugular intrahepatic portosystemic shunt for the management of severe venoocclusive disease following bone marrow transplantation. Hepatology 1996; 24: 588– 591. 8781329
  185. [187]Azoulay D, Castaing D, Lemoine A, Hargreaves GM, Bismuth E. Transjugular intrahepatic portosystemic shunt (TIPS) for severe veno-occlusive disease of the liver following bone marrow transplantation. Bone Marrow Transplant 2000; 25: 987– 992. 10800068
  186. [188]Wang X, Kanel G, DeLeve LD. Support of sinusoidal endothelial cell glutathione prevents hepatic venoocclusive disease in vivo. Hepatology 2000; 31: 428– 434. 10655267
  187. [189]DeLeve LD, Wang X, Kanel GC, Tokes ZA, Tsai J, Ito Y, Decreased Hepatic Nitric Oxide Production Contributes to the Development of Rat Sinusoidal Obstruction Syndrome. Hepatology 2003; 38: 900– 908. 14512877
  188. [190]DeLeve LD, Wang X, Tsai J, Kanel GC, Strasberg SM, Tokes ZA. Prevention of sinusoidal obstruction syndrome (hepatic venoocclusive disease) in the rat by matrix metalloproteinase inhibitors. Gastroenterology 2003; 125: 882– 890. 12949732
  189. [191]Koenecke C, Kleine M, Schrem H, Krug U, Nashan B, Neipp M, Sinusoidal obstruction syndrome of the liver after hematopoietic stem cell transplantation: decision making for orthotopic liver transplantation. Int J Hematol 2006; 83: 271– 274. 16720562
  190. [192]Mellgren K, Fasth A, Saalman R, Olausson M, Abrahamsson J. Liver transplantation after stem cell transplantation with the same living donor in a monozygotic twin with acute myeloid leukemia. Ann Hematol 2005; 84: 755– 757. 16001242
  191. [193]Kim I-D, Egawa H, Marui Y, Kaihara S, Haga H, Lin Y-W, A successful liver transplantation for refractory hepatic veno-occlusive disease originating from cord blood transplantation. Am J Transplant 2002; 2: 796– 800. 12243502
  192. [194]Janssen HL, Garcia-Pagan JC, Elias E, Mentha G, Hadengue A, Valla DC. Budd-Chiari syndrome: a review by an expert panel. J Hepatol 2003; 38: 364– 371. 12586305
  193. [195]Shrestha SM, Okuda K, Uchida T, Maharjan KG, Shrestha S, Joshi BL, Endemicity and clinical picture of liver disease due to obstruction of the hepatic portion of the inferior vena cava in Nepal. J Gastroenterol Hepatol 1996; 11: 170– 179. 8672764
  194. [196]Valla D Hepatic venous outflow tract obstruction etipathogenesis: Asia versus the West. J Gastroenterol Hepatol 2004; 19: S204– S211.
  195. [197]Ludwig J, Hashimoto E, McGill D, Heerden Jv. Classification of hepatic venous outflow obstruction:ambiguous terminology of the Budd-Chiari syndrome. Mayo Clin Proc 1990; 65: 51– 55. 2296212
  196. [198]Mehrotra G, Singh RP, Krishna A, Singh BK. Pyogenic liver abscess causing acute Budd-Chiari syndrome. Ann Trop Paediatr 1992; 12: 451– 453. 1283677
  197. [199]Uddin W, Ramage JK, Portmann B, Wilson P, Benjamin I, Tan KC, Hepatic venous outflow obstruction in patients with polycystic liver disease: pathogenesis and treatment. Gut 1995; 36: 142– 145. 7890219 PMC1382369
  198. [200]Rangheard AS, Vilgrain V, Audet P, O’Toole D, Vullierme MP, Valla D, Focal nodular hyperplasia inducing hepatic vein obstruction. AJR Am J Roentgenol 2002; 179: 759– 762. 12185058
  199. [201]Kubo T, Shibata T, Itoh K, Maetani Y, Isoda H, Hiraoka M, Outcome of percutaneous transhepatic venoplasty for hepatic venous outflow obstruction after living donor liver transplantation. Radiology 2006; 239: 285– 290. 16567488
  200. [202]Wang SL, Sze DY, Busque S, Razavi MK, Kee ST, Frisoli JK, Treatment of hepatic venous outflow obstruction after piggyback liver transplantation. Radiology 2005; 236: 352– 359. 15955856

200 of 366 shown

Cited by

Sorted by citations

Authors
DeLeve, L. D., Valla, D.-C., & Garcia-Tsao, G.
Affiliations
  • University of Southern California (US)
  • Inserm (FR)
ORCID
Venue
Hepatology
Publisher
Ovid Technologies (Wolters Kluwer Health)
Published
2009-05
Volume
49
Issue
5
Pages
1729-1764
ISSN
0270-9139 (ISSN-L)
DOI
10.1002/hep.22772
PMC
PMC6697263
OpenAlex
W1986963195
Cited by
978
References
1
Citations by year
2026: 32 · 2025: 34 · 2024: 31 · 2023: 51 · 2022: 50 · 2021: 58 · 2020: 74 · 2019: 78 · 2018: 65 · 2017: 70 · 2016: 65 · 2015: 77 · 2014: 86 · 2013: 57 · 2012: 59
FWCI
21.38
Type
journal article
Language
en
Open access
Licence
doi.wiley.com/10.1002/tdm_license_1.1 (tdm, 2314 d)
Locations
  • Hepatology (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • American Association for the Study of Liver Diseases
  • National Institute of Diabetes and Digestive and Kidney Diseases (R01DK046357)
Topics
  • Health Sciences › Medicine › Hepatology › Liver Disease and Transplantation
  • Health Sciences › Medicine › Surgery › Abdominal vascular conditions and treatments
  • Health Sciences › Medicine › Hepatology › Liver Diseases and Immunity
Keywords
veno-occlusive disease, portal hypertension, liver cirrhosis, hepatic vein thrombosis, liver transplantation, diagnostic assessment, treatment management, prevention
MeSH terms
Child, Budd-Chiari Syndrome, Hepatic Veno-Occlusive Disease, Humans, Liver Cirrhosis, Portal Vein, Telangiectasia, Hereditary Hemorrhagic, Liver Transplantation, Venous Thrombosis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review